JP2012515210A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012515210A5 JP2012515210A5 JP2011546322A JP2011546322A JP2012515210A5 JP 2012515210 A5 JP2012515210 A5 JP 2012515210A5 JP 2011546322 A JP2011546322 A JP 2011546322A JP 2011546322 A JP2011546322 A JP 2011546322A JP 2012515210 A5 JP2012515210 A5 JP 2012515210A5
- Authority
- JP
- Japan
- Prior art keywords
- free base
- bendamustine free
- degrees
- ray powder
- crystalline form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical group ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims description 51
- 239000000843 powder Substances 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 28
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229960002707 bendamustine Drugs 0.000 description 2
- 229960001215 bendamustine hydrochloride Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940066958 treanda Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14484309P | 2009-01-15 | 2009-01-15 | |
| US61/144,843 | 2009-01-15 | ||
| PCT/US2010/020992 WO2010083276A1 (en) | 2009-01-15 | 2010-01-14 | Novel forms of bendamustine free base |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012515210A JP2012515210A (ja) | 2012-07-05 |
| JP2012515210A5 true JP2012515210A5 (enExample) | 2013-02-28 |
Family
ID=42008533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011546322A Pending JP2012515210A (ja) | 2009-01-15 | 2010-01-14 | ベンダムスチン遊離塩基の新規の形態 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8076366B2 (enExample) |
| EP (1) | EP2387400A1 (enExample) |
| JP (1) | JP2012515210A (enExample) |
| KR (1) | KR20110110293A (enExample) |
| CN (2) | CN102281877B (enExample) |
| AU (2) | AU2010204765A1 (enExample) |
| BR (1) | BRPI1004922A2 (enExample) |
| CA (1) | CA2749101A1 (enExample) |
| EA (1) | EA020767B1 (enExample) |
| IL (1) | IL213725A0 (enExample) |
| MX (1) | MX2011007557A (enExample) |
| NZ (1) | NZ594010A (enExample) |
| SG (1) | SG172810A1 (enExample) |
| UA (1) | UA109109C2 (enExample) |
| WO (1) | WO2010083276A1 (enExample) |
| ZA (1) | ZA201105099B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9376394B2 (en) * | 2009-12-23 | 2016-06-28 | Dr. Reddy's Laboratories Ltd. | Preparation of bendamustine and its salts |
| PL3158991T3 (pl) | 2010-01-28 | 2021-09-27 | Eagle Pharmaceuticals, Inc. | Preparaty bendamustyny |
| EP2720547A4 (en) * | 2011-06-20 | 2014-11-05 | Hetero Research Foundation | PROCESS FOR BENDAMUSTINE HYDROCHLORIDE |
| EP4360621A3 (en) | 2012-03-20 | 2024-05-22 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| PT3533447T (pt) | 2012-03-20 | 2023-05-17 | Eagle Pharmaceuticals Inc | Composições líquidas de bendamustina para utilização num método de tratamento de condições com resposta a bendamustina em pacientes que requerem volumes reduzidos para administração |
| US20230241218A1 (en) * | 2012-07-10 | 2023-08-03 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| US9598377B2 (en) * | 2013-03-12 | 2017-03-21 | Cephalon, Inc. | Nanoparticulate and macroparticulate formulations |
| EP2988655B1 (en) | 2013-04-26 | 2023-04-12 | Genentech, Inc. | Contour integration perimetry vision test |
| US20240148696A1 (en) | 2022-10-25 | 2024-05-09 | Softkemo Pharma Inc. | Lyophilized bendamustine-cyclodextrin composition |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE293808C (enExample) | ||||
| DE80967C (enExample) | ||||
| DE159877C (enExample) | ||||
| DD159289A1 (de) | 1981-06-01 | 1983-03-02 | Uwe Olthoff | Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen |
| DD159877A1 (de) * | 1981-06-12 | 1983-04-13 | Wolfgang Krueger | Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure |
| US5204335A (en) * | 1986-10-31 | 1993-04-20 | Asta Pharma Aktiengesellschaft | Ifosfamide lyophilisate and process for its preparation |
| US5227373A (en) * | 1991-10-23 | 1993-07-13 | Bristol-Myers Squibb Co. | Lyophilized ifosfamide compositions |
| RU2139731C1 (ru) * | 1992-11-13 | 1999-10-20 | Айдек Фармасьютикалс Корпорейшн (US | Способ лечения, антитела, гибридома |
| US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| CN1060042C (zh) * | 1993-10-27 | 2001-01-03 | 法玛西雅厄普约翰美国公司 | 稳定的前列腺素e1 |
| US5561121A (en) | 1993-11-09 | 1996-10-01 | American Cyanamid Company | Stable lyophilized thiotepa composition |
| US5955504A (en) * | 1995-03-13 | 1999-09-21 | Loma Linda University Medical Center | Colorectal chemoprotective composition and method of preventing colorectal cancer |
| DE19529057B4 (de) * | 1995-08-08 | 2007-12-13 | Baxter Healthcare S.A. | Ifosfamid-Lyophilisat-Zubereitungen |
| US20040072889A1 (en) * | 1997-04-21 | 2004-04-15 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia |
| US6034256A (en) * | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
| US6077850A (en) * | 1997-04-21 | 2000-06-20 | G.D. Searle & Co. | Substituted benzopyran analogs for the treatment of inflammation |
| AU767586B2 (en) * | 1998-07-09 | 2003-11-20 | Cephalon, Inc. | Methods and compositions for the treatment of chronic lymphocytic leukemia |
| US5972912A (en) * | 1998-12-17 | 1999-10-26 | S.P. Pharmaceuticals | Method for lyophilizing ifosfamide |
| US6569402B1 (en) * | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| US6380210B1 (en) * | 1999-04-02 | 2002-04-30 | Neurogen Corporation | Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors |
| US6545034B1 (en) * | 1999-07-23 | 2003-04-08 | The Regents Of The University Of California | Use of etodolac for the treatment of chronic lymphocytic leukemia |
| DE10016077A1 (de) | 2000-03-31 | 2001-12-13 | Cellcontrol Biomedical Lab Gmb | Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen |
| US20040152672A1 (en) * | 2000-08-09 | 2004-08-05 | Carson Dennis A. | Indole compounds useful for the treatment of cancer |
| KR20040025880A (ko) * | 2000-12-11 | 2004-03-26 | 다케다 야쿠힌 고교 가부시키가이샤 | 수용해성이 개선된 의약 조성물 |
| AU2002221115A1 (en) * | 2000-12-11 | 2002-06-24 | Takeda Chemical Industries Ltd. | Medicinal compositions having improved absorbability |
| CA2462723C (en) * | 2001-10-15 | 2012-05-01 | Hemoteq Gmbh | Coated stents for preventing restenosis |
| US6613927B1 (en) | 2002-02-08 | 2003-09-02 | American Pharmaceutical Partners, Inc. | Sterile lyophilized ifosfamide and associated methods |
| DE10306724A1 (de) | 2002-02-28 | 2003-09-18 | G O T Therapeutics Gmbh | Vesikuläre Verkapselung von Bendamustin |
| WO2003081238A2 (en) | 2002-03-22 | 2003-10-02 | Ludwig Maximilians Universität | Cytocapacity test |
| EP1354952A1 (en) | 2002-04-17 | 2003-10-22 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Smac-peptides as therapeutics against cancer and autoimmune diseases |
| EP1495124A2 (en) | 2002-04-17 | 2005-01-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Smac-peptides as therapeutics against cancer and autoimmune diseases |
| WO2003094990A1 (de) | 2002-05-09 | 2003-11-20 | Hemoteq Gmbh | Verbindungen und verfahren zur hemokompatiblen beschichtung von oberflächen |
| AU2003258061A1 (en) * | 2002-08-02 | 2004-02-23 | Salmedix, Inc. | Therapeutic inhibitionof protein kinases in cancer cells |
| DE10304403A1 (de) | 2003-01-28 | 2004-08-05 | Röhm GmbH & Co. KG | Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung |
| EP1444989A1 (en) | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
| WO2004074325A2 (en) * | 2003-02-14 | 2004-09-02 | Salmedix, Inc | Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers |
| MXPA05013865A (es) * | 2003-07-25 | 2006-02-28 | Wyeth Corp | Formulaciones liofilizadas de cci-779. |
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| JP5773874B2 (ja) * | 2008-10-08 | 2015-09-02 | セファロン、インク． | ベンダムスチンの調製方法 |
-
2010
- 2010-01-14 AU AU2010204765A patent/AU2010204765A1/en not_active Abandoned
- 2010-01-14 EA EA201170934A patent/EA020767B1/ru not_active IP Right Cessation
- 2010-01-14 CA CA2749101A patent/CA2749101A1/en not_active Abandoned
- 2010-01-14 MX MX2011007557A patent/MX2011007557A/es active IP Right Grant
- 2010-01-14 BR BRPI1004922A patent/BRPI1004922A2/pt not_active IP Right Cessation
- 2010-01-14 NZ NZ594010A patent/NZ594010A/xx unknown
- 2010-01-14 EP EP10701071A patent/EP2387400A1/en not_active Withdrawn
- 2010-01-14 WO PCT/US2010/020992 patent/WO2010083276A1/en not_active Ceased
- 2010-01-14 UA UAA201109971A patent/UA109109C2/uk unknown
- 2010-01-14 CN CN201080004743.6A patent/CN102281877B/zh not_active Expired - Fee Related
- 2010-01-14 US US12/687,398 patent/US8076366B2/en not_active Expired - Fee Related
- 2010-01-14 SG SG2011047875A patent/SG172810A1/en unknown
- 2010-01-14 KR KR1020117018325A patent/KR20110110293A/ko not_active Ceased
- 2010-01-14 JP JP2011546322A patent/JP2012515210A/ja active Pending
- 2010-01-14 CN CN201310425128.8A patent/CN103554030A/zh active Pending
-
2011
- 2011-06-22 IL IL213725A patent/IL213725A0/en unknown
- 2011-07-11 ZA ZA2011/05099A patent/ZA201105099B/en unknown
-
2016
- 2016-07-13 AU AU2016204902A patent/AU2016204902A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012515210A5 (enExample) | ||
| JP2009515988A5 (enExample) | ||
| JP2010241830A5 (enExample) | ||
| JP2012526808A5 (enExample) | ||
| TWI672305B (zh) | 一種ｊａｋ激酶抑制劑的硫酸氫鹽的結晶形式及其製備方法 | |
| JP2009542787A5 (enExample) | ||
| US20250281492A1 (en) | New crystalline forms of salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide | |
| TWI675839B (zh) | 一種ｊａｋ激酶抑制劑的硫酸氫鹽的結晶形式及其製備方法 | |
| MY150289A (en) | Derivatives of indole-2-carboxamides and of azaindole-2-carboxamides substituted with a silanyl group, preparation thereof and therapeutic use thereof | |
| EP2970123A1 (en) | Salt of omecamtiv mecarbil and process for preparing salt | |
| JP2020517611A5 (enExample) | ||
| JP2012513416A5 (enExample) | ||
| JP2018531987A5 (enExample) | ||
| JP2014506582A5 (enExample) | ||
| WO2014059518A9 (en) | Solid forms of nilotinib hydrochloride | |
| AU2009293444B2 (en) | Salts of N-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'- (trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide | |
| JP2009537532A5 (enExample) | ||
| CA2767992A1 (en) | 2 - [[[2 -[(hydroxyacetyl) amino]- 4 -pyridinyl] methyl] thio]- n -[4 - (trifluoromethoxy) phenyl]- 3 -pyridinecarboxamide benzenesulfonate, crystal of same, crystal polymorph thereof, and methods for production thereof | |
| JP2016172741A5 (enExample) | ||
| JP2012504631A5 (enExample) | ||
| CN103275024B (zh) | 一种氮唑类抗真菌化合物及其制备方法和用途 | |
| WO2016151304A1 (en) | Novel polymorphic form x of nilotinib dihydrochloride hydrate | |
| CN111479808A (zh) | 嘧啶磺酰胺类衍生物、其制备方法及其在医药上的应用 | |
| JP2013525455A5 (enExample) | ||
| JP2008544975A5 (enExample) |